Clinical trials: Stage IIA Rectal Cancer
Urinary Bladder Neoplasms, Colorectal Cancer
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
- Conditions
- Urinary Bladder Neoplasms, Colorectal Cancer, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT05397171
- Testing
- AZD8853, Zirconium-89 crefmirlimab berdoxam
- Where
- 6 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Colorectal Cancer Metastatic
Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS)
This study will enroll patients with colorectal cancer that is locally advanced or metastatic. The tumor must be microsatellite stable (MSS), have a tumor mutational burden that is high (TMB-H) and be kras mutated.
- Trial name
- NCT06634875
- Testing
- isunakinra
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Buzzard Pharmaceuticals
Colorectal Carcinoma
Neoadjuvant Recombinant Vaccinia Virus for Metastatic Colorectal Cancer With Liver Resection
This is a neoadjuvant Phase 2a, open-label trial in patients with metastatic colorectal carcinoma who are undergoing a complete resection of the metastatic colorectal tumors in their liver.
- Trial name
- NCT01329809
- Testing
- Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- Jennerex Biotherapeutics
Ovarian Neoplasms, Prostatic Neoplasms
A Study of DM002 in Patients With Advanced Solid Tumors
The goal of study： The study has two parts: Part 1 Dose Escalation and Part 2 Dose Expansion. In Part 1, a few participants will receive the lowest dose of study drug.
- Conditions
- Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Colorectal Neoplasms
- Trial name
- NCT06751329
- Testing
- DM002
- Where
- 7 sites in United States, Australia
- Volunteers
- 280 people
- Sponsor
- Xadcera Biopharmaceutical (Suzhou) Co., Ltd.
Metastatic Colorectal Cancer, Prostate Cancer Metastatic
A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC
This is a First-In-Human trial investigating a novel expansion protocol of an ATIMP (CC-38), composed of autologous TIL.
- Conditions
- Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced
- Trial name
- ProbeTILity (NCT07255664)
- Testing
- CC-38, Pembrolizumab, Cyclophosphamid
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- CuraCell TX AB
Melanoma, Head and Neck Squamous Cell Carcinoma
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours.
- Conditions
- Melanoma, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
- Trial name
- NCT06305247
- Testing
- IPN01194
- Where
- 12 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- Ipsen
Colorectal Neoplasms
Cetuximab in Refractory Colorectal Cancer With K-RAS Mutated and Favorable FcγRIIa (CD32) Genotype
This national, multicenter, open-label phase 2 study without any control arm aims to evaluate the activity of cetuximab monotherapy in the treatment of refractory colorectal cancer in subjects with K-RAS mutated and FcγRIIa…
- Trial name
- MUTEX (NCT01450319)
- Testing
- Cetuximab
- Where
- 9 sites in Spain
- Volunteers
- 73 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Colorectal Neoplasms, Colonic Neoplasms
EPO906 Therapy in Patients With Advanced Colorectal Cancer
This study will examine whether the new investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause colorectal cancer.
- Trial name
- NCT00035087
- Testing
- epothilone b
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer Metastatic
AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer
This is a single center, open label dose frequency escalation study of CryoVax®. personalized anti-tumor vaccine protocol combining the cryoablation of a selected metastatic lesion with intra-lesional immunotherapy with…
- Trial name
- NCT02380443
- Testing
- AlloStim, Cryoablation
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Mirror Biologics, Inc.